• LAST PRICE
    1.0100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 1.0100
  • Day Range
    ---
  • 52 Week Range
    Low 1.0100
    High 1.0100
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCTBO
Cantabio Pharmaceuticals Inc
22.8K
0.0x
---
United StatesARNI
Arno Therapeutics Inc
14.8K
0.0x
---
United StatesVRCI
Verde Science Inc
20.0
0.0x
---
United StatesEAPH
Easton Pharmaceuticals Inc
1.3K
0.0x
---
United StatesVOQP
Vioquest Pharmaceuticals Inc
43.1K
0.0x
---
United StatesSCPS
Scopus Biopharma Inc
46.3K
0.0x
---
As of 2024-04-25

Company Information

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company. The Company is focused on commercializing therapies and the intellectual property generated from its research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. The Company’s small molecule therapy candidates program (CB101) and protein therapy candidate (CB201) targets Parkinson’s disease and a range of neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease and stroke. It also has two additional small molecule pharmacological chaperone programs for the treatment of Alzheimer’s Disease (and other related dementias); CB301, targeting the Tau protein, for the development of Alzheimer’s therapeutics, and CB401, targeting the Aß peptide in Alzheimer’s drug research. The Company’s strategy integrates therapeutic focus on targeting family biophysics and drug discovery technology.

Contact Information

Headquarters
2225 East Bayshore Road, Suite 200PALO ALTO, CA, United States 94303
Phone
302-645-7400
Fax
302-636-5454

Executives

Chief Executive Officer
Gergely Toth
Chief Operating Officer
Thomas Sawyer
Director
Max Zhu

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$22.8K
Revenue (TTM)
$0.00
Shares Outstanding
22.6K
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-177.35
Book Value
$-180.46
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.